Rising oil prices amid escalating Middle East tensions between the US and Iran are driving market volatility and inflation concerns. The Federal Reserve is expected to hike interest rates next month. Investors are rotating toward defensive stocks in consumer staples and healthcare sectors.

Assembli has been selected to design and produce the Big Ten Conference's first-ever fan experience at Fanatics Fest NYC (July 16-19, 2026), making the Big Ten the first collegiate conference to participate in the event. The activation will feature the Heisman Trophy, CFP National Championship Trophy, interactive games, and fan engagement activities. Assembli will also return for its third consecutive year to produce the Big Ten Championship Fan Fest in December 2026.

Assembly Biosciences announced that its Chief Medical Officer, Anuj Gaggar, MD, PhD, will present at the Bank of America Securities 2026 Global Health Care Conference on May 13, 2026. The company also highlighted positive Phase 1b data for its helicase-primase inhibitors ABI-5366 and ABI-1179 for recurrent genital herpes treatment, with additional data selected for oral presentation and late-breaker poster presentation at ESCMID Global 2026.

Assembly Biosciences reported Q1 2026 financial results with cash reserves of $226.6 million, sufficient to fund operations into 2028. The company completed Phase 1b studies for herpes candidates ABI-5366 and ABI-1179 (licensed to Gilead) and chronic toxicology studies for hepatitis delta virus candidate ABI-6250, with Phase 2 initiation expected in Q4 2026. Net loss was $9.1 million for the quarter.

Assembly's NeosAI, built on Microsoft Azure AI Foundry, has demonstrated significant time savings and workflow automation for law firms, with advanced natural language processing and enterprise-grade security.

Insiders have been purchasing shares in American Software, Assembly Biosciences, and Tile Shop Holdings, indicating their confidence in the companies' prospects.

– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 –

Here is how Entera Bio Ltd. (ENTX) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) have performed compared to their sector so far this year.

SOUTH SAN FRANCISCO, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results and recent highlights for the fourth quarter and year ended December 31, 2023.

Shares of Icosavax, Inc. (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion. Icosavax also reported topline interim Phase 2 results for combination VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults. Icosavax shares gained 44.8% to $15.19 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Bruush Oral Care Inc. (NASDAQ: BRSH) shares rose 76.8% to $0.2882 in pre-market trading after gaining over 5% on Monday. Connect Biopharma Holdings Limited (NASDAQ: CNTB) rose 32.2% to $1.19 in pre-market trading. Connect Biopharma will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on Dec. 12, 2023. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) shares rose 28% to $0.3159 in pre-market trading. Kaival Brands recently appointed James W. Dobbins as General Counsel. IN8bio, Inc.(NASDAQ: INAB) gained ...

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced a grant of inducement awards to its chief medical officer, Anuj Gaggar, MD, PhD on November 8, 2023.